Prior to the clinical evaluation at our center, 85% of patients who underwent SLB had nondiagnostic transbronchial biopsy. The diagnosis of IPF and ILD other than IPF was accurately made by clinical features alone in 62% of cases. The correct radiographic diagnosis of non-IPF ILD was made in 58% of the cases. The sensitivity and specificity of the clinical diagnosis of ILD other than IPF were 88.8% and 40%, respectively. The sensitivity and specificity of the radiographic diagnosis of ILD other than IPF were 59% and 40%, respectively. However, the sensitivity and specificity of the diagnosis of IPF on clinical grounds were 62% and 97%, respectively. The sensitivity and specificity of the radiologic diagnosis of IPF were 78.5% and 90%, respectively. Conclusions: In a center with recognized expertise in the management of ILD, the specificity of diagnosis of new-onset IPF based on a thorough clinical assessment or HRCT features alone is very high (97% and 90%, respectively), but the sensitivity is low (62% and 78.5%, respectively). Thus, not all patients with new-onset IPF require SLB for diagnosis, but a diagnosis of IPF will be missed in nearly one third of new-onset IPF cases despite evaluation by experts. The relatively low sensitivity and specificity of the diagnosis of ILD other than IPF also emphasizes that an SLB is indicated in patients with ILD in whom the diagnosis is unclear.
I
n the apparently normal host, interstitial lung disease (ILD) represents a heterogenous group of noninfectious, acute and chronic, diffuse parenchymal lung disorders. Because there are more than 150 clinical conditions and/or causes associated with ILD, an accurate diagnosis is essential to determine prognosis and appropriate therapeutic intervention for a given patient. Histologic features found in surgical lung biopsy (SLB) specimens (either open lung biopsy or thoracoscopic lung biopsy) often provide a specific diagnosis; therefore, SLB is the gold standard for the diagnosis of ILD. 1, 2 With current advances in technology, the need for SLB in every patient with suspected ILD and idiopathic pulmonary fibrosis (IPF) has been recently questioned. 3 A clinical diagnosis, in conjunction with distinct distribution patterns and anatomic variability on high-resolution computed tomography (HRCT) scans of the chest, has led to a specific diagnosis of ILD being made based on HRCT features alone. 4 -6 However, the accuracy and predictive value of a clinical diagnosis is unknown and has yet to be determined. The validity of a test is measured by its ability to correctly categorize patients with and without disease. Sensitivity (proportion of individuals with the disease who have a positive test) and specificity (proportion of individuals without the disease in question who have a negative test) are measures of validity. The predictive value measures whether or not an individual has the disease given the results of the test. The positive predictive value (PPV) is the probability that an individual has the disease based on a positive test. Conversely, the negative predictive value (NPV) is the probability that an individual does not have the disease in question based on a negative test. 7, 8 In order to determine the need for an SLB in every patient with new-onset ILD, we tested the hypothesis that a clinical diagnosis based on thorough clinical assessment including HRCT and bronchoscopy findings is both sensitive and specific when compared with the histopathologic diagnosis.
Materials and Methods

Subjects
The study population was composed of all symptomatic, adult, untreated patients with ILD consecutively referred to a senior ILD specialist (GR) for diagnostic evaluation of new-onset ILD without a specific diagnosis at the University of Washington Medical Center in Seattle, WA. tive interstitial pneumonia/respiratory bronchiolitis, acute interstitial pneumonia, eosinophilic pneumonia, or bronchiolitis obliterans organizing pneumonia. 12 Excluded were patients who (1) had an established diagnosis based on accepted histologic criteria prior to referral; (2) had a diagnostic transbronchial lung biopsy (TBBX); (3) had an established diagnosis of systemic lupus erythematosus, progressive systemic sclerosis, rheumatoid arthritis, dermatopolymyositis (based on accepted diagnostic criteria defined by American Rheumatological Association); (4) had abnormal BUN and creatinine; (5) had a history of having been treated for ILD; (6) had clinical evidence of advanced IPF [clinically advanced IPF was defined as (1) an unexplained insidious onset of breathlessness with exertion with or without a cough of Ͼ 3 years' duration; (2) physical findings of late inspiratory rales at both lung bases with or without clubbing; (3) chest radiographic and/or HRCT evidence of progressive intralobular and interstitial reticular opacities other than ground glass; irregular interlobular septal thickening, and diffuse honeycombing in both lungs (not restricted to the subpleural and lower lung zones) associated with traction bronchiectasis on HRCT 8, 9 ]; (7) had evidence of overt right or left heart failure on physical examination; or (8) refused SLB.
Definitions
Protocol
All patients referred during the period from 1992 to 1997 for further diagnostic evaluation of nonspecific ILD were considered potential candidates. Institutional review board approval was obtained to collect clinical data from all patients referred for management of ILD at our center. Patients meeting the criteria were prospectively evaluated by the senior ILD specialist (G.R.). A detailed and thorough clinical assessment was performed in accordance with a previously outlined algorithm, 3 an ongoing clinical practice at our center and by most practicing pulmonologists in the state of Washington. Data collected included (1) demographic: age, sex, race, smoking status; (2) physiologic: pulmonary function tests including spirometry, lung volumes, and diffusing capacity of carbon monoxide; (3) radiographic: standard chest radiographs and HRCT using state-of-the-art equipment and techniques; (4) laboratory values including CBC count, routine chemistries including BUN, creatinine, liver enzymes, serology for collagen-vascular disease or vasculitis, antinuclear antigens, erythrocyte sedimentation rate, and rheumatoid factor (antiglomerular basement antibody and antineutrophil cytoplasmic antibody levels were obtained in the appropriate clinical setting). Because our patient population did not have known risk factors for HIV infection, routine HIV testing was not performed.
The clinical assessment included re-elicitation and clarification of detailed medical, family, occupational, social, and drug history; a review of questionnaires filled out by patients; a physical examination; and review of laboratory data, pulmonary function tests, bronchoscopy, and chest radiograph and HRCT findings. The histologic features of TBBX in patients who had undergone bronchoscopy were included in the assessment. 3 Immediately following the review of all subjective and objective findings, the specialist documented the most likely specific diagnosis based on his overall clinical assessment. Histopathologic specimens from subjects who had undergone TBBX by referring community pulmonologists were reviewed by our pulmonary pathologist (R.A.S.). The cellular analysis of BAL was not included in the assessment. This is because the utility of cellular profile of BAL as a diagnostic tool in ILD is controversial, and the procedure is not routinely done as a standard of care in the state of Washington. At our center, we have documented the insensitivity and nonspecificity of BAL in sarcoidosis and other ILD, respectively. 10, 11 The chest radiographs and HRCT scans were also read independently by a senior chest radiologist (J.D.G.) who made a most likely specific diagnosis based solely on radiographic and HRCT features. To simulate a typical clinical situation, the radiologist was only aware that the chest radiographs and HRCT scans were being obtained to rule out ILD. Prior to SLB, neither the radiologist's report nor the clinical diagnosis independently made by the ILD specialist was made available to one another or to the pathologist.
All consenting patients in whom a diagnosis was not clearly established by characteristic histologic features on TBBX underwent SLB within 1 month of their initial clinical assessment. The SLB was recommended to the patient for the sake of clarifying the diagnosis in the interest of patient care and not only for the purpose of the study. At least two separate biopsy specimens from the same lung were obtained; the site and side were based on preoperative HRCT findings representative of the diffuse parenchymal disease. 3 The biopsy slides were interpreted by a senior pulmonary pathologist (R.A.S.) familiar with current and evolving terminology, subgroups, classifications, and characteristic histologic features of various specific ILDs, idiopathic interstitial pneumonias, and IPF. 12 These include features of usual interstitial pneumonitis (UIP) for IPF, nonspecific interstitial pneumonia (NSIP), and, in the absence of infection, typical noncaseating granulomas of sarcoidosis and hypersensitivity pneumonitis. While aware that the SLB was obtained for diagnosis of ILD, the pathologist was blinded to all other details of the clinical findings and diagnosis made independently by the clinician and the chest radiologist. The pathologist was, however, specifically alerted to the clinical suspicion of vasculitis and collagen-vascular disease in two patients who had suggestive clinical features. The histologic features of SLB were used as the reference standard for an accurate diagnosis to compare and confirm the clinical and radiologic diagnoses made prior to SLB.
Analysis
Data collected was analyzed independently (Y.N.M.) for sensitivity and specificity. Three specific areas were examined: (1) the sensitivity and specificity for ILD other than IPF; (2) the sensitivity and specificity for IPF; and (3) the PPVs and NPVs for the clinical diagnosis of ILD other than IPF.
Results
A total of 59 patients met criteria for the study from 1992 to 1997 (Table 1) . Eighty-five percent of subjects had undergone nondiagnostic TBBX before undergoing SLB. Based on the patient's clinical status (eg, patients ability to tolerate TBBX, high suspicion for malignancy, etc) and/or preference, 9 of 59 patients (15%) were directly referred for SLB. Patients' ages ranged from 24 to 78 years (median, 53 years); and there were 24 women and 35 men. The median duration of symptoms was 14 months (range, 3 to 24 months) Four were current smokers (7%), 21 were nonsmokers (35%), and 34 were previous smokers (defined as having stopped smoking within 6 months of presentation; 58%). The HRCT features noted are described in Table 2 . All but two subjects were noted to have various bilateral parenchymal abnormalities on HRCT. The two subjects with normal scans had histologic diagnoses of hypersensitivity pneumonitis and respiratory bronchiolitis, respectively. Table 3 shows the specific diagnoses of ILD based on histologic characteristics. Table 4 shows the percentage of correct clinical and radiologic diagnoses compared with the histologic diagnoses. (The histologic features of UIP alone were the accepted histologic features for IPF. 12 )
The clinical diagnosis of ILD other than IPF was accurate in 61% of the cases, and the clinical diagnosis of IPF was accurate in 62% of all patients with UIP. Based on HRCT and chest radiograph alone, the radiologist made an accurate diagnosis of ILD other than IPF in 58% of the cases and of IPF in 76% of the cases. The sensitivity of the clinical diagnosis of ILD other than IPF was 88.8%, while the specificity was lower, at 40% (Fig 1) . The sensitivity and specificity of a radiologic diagnosis of ILD other than IPF were significantly lower: 59% and 40%, respectively (Fig 1) . The sensitivity of the clinical diagnosis of IPF was only 62%; the specificity, however, was very high, 97% (Fig 1) . The sensitivity and specificity of a radiologic diagnosis of IPF were 78.5% and 90%, respectively (Fig 1 and Table 5 ). The PPV of the clinical diagnosis of IPF was 95% and the NPV was 73%. The PPV and NPV of the clinical diagnosis of ILD other than IPF were 94% and 25%, respectively ( Table 5 ). The PPV and NPV for a radiologic diagnosis of ILD were 91% and 8%, respectively (Table 6 ). In contrast, the PPV and NPV for a radiologic diagnosis of IPF were 88% and 82%, respectively (Table 6 ).
Discussion
Over the last few years, the abnormal patterns of ILD and IPF on HRCT scans have been refined and are being increasingly recognized as diagnostic patterns. This has led to the increasing use of HRCT scans in conjunction with a thorough clinical assessment; it has been suggested that an accurate diagnosis of ILD can be made without SLB. 3,13 An *Includes pneumothorax (n ϭ 1), pleural effusions (n ϭ 3), thickening (n ϭ 2), calcified pleural plaque (n ϭ 1). The present study is the first to prospectively determine the pretest probability of the clinical diagnosis of ILD. It is important to note that in our results, IPF was singled out from other specific forms of ILD because it is considered to be the prototype of ILD and because the majority of patients with new-onset ILD are determined to have IPF based on histologic features of UIP.
Following a thorough clinical assessment and a negative bronchoscopy, clinicians are tempted to label a patient with a "diagnosis of IPF." Some clinicians question the necessity to subject such patients to SLB for diagnostic and prognostic purposes because current therapeutic regimens for IPF and related disorders are not only ineffective, but also associated with significant morbidity and poor outcome. Thus, when clinicians make a presumptive clinical diagnosis of IPF, they debate the absolute need for SLB in patients similar to the ones evaluated in this study. Because 85% of the patients had a nondiagnostic TBBX prior to referral to our center, the diagnosis of IPF was assumed as such by the community physicians. In fact, there was histologic confirmation of UIP in only 29 of 59 cases, and the diagnosis made on clinical grounds alone was correct in only 62% of the confirmed cases of IPF. Other categories of ILD would, therefore, have been erroneously labeled as IPF if the patients had not undergone SLB (Table 4) . Recently, the prognostic significance of microscopic features and histologic subgroups was documented in a retrospective study of patients in whom apparent IPF was previously diagnosed. 14 In retrospect, several patients were misclassified as having IPF, and patients whose lung biopsy specimens had features consistent with currently recognized entity of NSIP had better prognosis than those with UIP. If we had not subjected our patients to SLB, we would have missed the diagnosis of IPF in over one third of all new IPF cases and would not have recognized the histologic subsets despite a thorough clinical assessment in nearly one fourth of cases based on HRCT features alone. Even though a false diagnosis of IPF would have been made in only 2% of the cases based on a thorough clinical assessment alone using defined clinical criteria (as defined in the "Materials and Methods" section), it must be reiterated that the same clinician still missed more than one third of all new-onset IPF cases that he prospectively evaluated during the study period. Likewise, the chest radiologist was also unable to make a specific diagnosis of new-onset IPF in one fourth of cases based on chest radiographic and HRCT features alone. Although normal HRCT scans have been reported in patients with IPF, 15 our findings do not support this. In fact, normal HRCT findings were present in only 2 of the 59 patients with nonspecific ILD; neither of these patients had IPF. Our patients all had new-onset ILD, and none of the 29 patients with early IPF in our study had a normal HRCT scan; thus, findings of a normal HRCT scan should be considered a rarity in IPF, if not incompatible with an IPF diagnosis. We note that the clinical diagnosis was accurate in only two thirds of cases, for both IPF and other types of ILD; however, the specificity of the clinical diagnosis of IPF was 97%. This is obviously very high and should raise the possibility that the very high specificity of the clinical diagnosis of IPF in this study may indeed be related to our vast experience in the management of this disease. Although one may point out a referral bias in this study, the low sensitivity of the diagnosis made by both the clinician and chest radiologist in our center lends support to the need for SLB to make an accurate diagnosis of new-onset ILD. The sensitivity of the clinical diagnosis of IPF made by a general pulmonologist may be lower than for an ILD expert, and even lower when made by a primary-care general physician (family practitioner or internist). The accurate diagnosis of IPF is important for patient care, and it is also particularly important in the design of future clinical studies, given that at least one third of cases of early IPF may still be missed if investigators rely on clinical diagnosis using the criteria as outlined in the "Materials and Methods" section. Clearly, it is difficult or nearly impossible to make specific diagnoses based on histologic subsets such as lymphocytic interstitial pneumonia or NSIP on clinical grounds and/or HRCT findings prior to initiation of treatment. Because of the differential prognostic significance and treatment regimen in this subset of patients, a pathologic diagnosis is required to make an accurate diagnosis of ILD and predict therapeutic response before a treatment regimen is initiated.
Our study has several limitations, including referral bias. The study was performed in one center only, with a relatively small number of patients with true new-onset, undiagnosed ILD. Also, we used only one investigator/expert per arm, and did not assess interobserver variability in the diagnosis of ILD. Had we found a high sensitivity and specificity for the clinical diagnosis of ILD other than IPF and a high sensitivity for the clinical diagnosis of IPF, one could indeed suppose that our findings may not be applicable to patients evaluated by community pulmonary clinicians. Although there are clear merits of a multicenter study with an expert panel of ILD clinicians, chest radiologists, and pulmonary pathologists, such a panel would not be able to evaluate the data as directly; in the present study, the data were evaluated at the bedside. In our study, an experienced clinician assessed both subjective (patient's) and objective measurements. Our clinician had the advantage of eliciting the medical history directly and personally reviewing all the clinical variables, including HRCT findings (without the benefit of the radiologist's input), in the direct context of that given patient immediately after examining him or her. In this regard, our findings may indeed be applicable to patients evaluated by prudent pulmonologists in community or academic practice, especially if patients are evaluated in a systematic manner, 3 as in this study (see "Materials and Methods" section). One important caveat is that we included only those individuals with new-onset ILD in whom the diagnosis was unclear. Hence, these results should not be extrapolated to patients with longstanding clinical features of advanced IPF (as defined in "Materials and Methods"). The diagnosis of such advanced IPF, especially with supporting HRCT features, after a careful thorough clinical assessment is a relatively straightforward one, and it can be accomplished on clinical grounds alone. 3 With increasing awareness, evolving knowledge, and clarification of the definitions of IPF and related disorders, it is hoped that the ability of all clinicians to make a clinical diagnosis of IPF will improve.
The design and focus of this study was not to address interobserver variability. Although there are no studies reported to date addressing this issue in ILD, preliminary results from a multicenter study examining interobserver variability (kappa) reveal findings similar to the present results. 16 In addition, the possibility of interobserver variability further supports the need for SLB when there is any degree of uncertainty regarding the diagnosis.
In summary, SLB remains the gold standard for an accurate diagnosis of ILD in symptomatic patients with new-onset ILD in whom the diagnosis remains unclear after a thorough clinical assessment. Although SLB is not needed for all patients with typical clinical features of IPF, SLB should be used to diagnose new-onset IPF when TBBX is nondiagnostic and the clinician is unable to make the clinical diagnosis of IPF with a high degree of certainty. Hopefully, clinical studies such as the present one and the emerging consensus among experts in defining IPF and related disorders will clarify typical clinical features of IPF for clinicians and enable them to recommend the most appropriate diagnostic intervention for each patient.
